January 13th, 2011
Merck’s Thrombin Receptor Antagonist Suffers Major Setback
Larry Husten, PHD
Merck’s thrombin receptor antagonist, vorapaxar, has suffered a major setback in its clinical trial program. In one trial, TRACER, the study drug is being discontinued and the trial will be closed out. The second trial, TRA-2P TIMI 50, is being curtailed but not stopped. The actions were based on recommendations from the combined Data and […]
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults